Lv42
620 积分 2022-07-17 加入
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial
7个月前
已关闭
Clinical Audit of Horizontal Strabismus Surgery in Children in Maharashtra, India
7个月前
已完结
Maintenance therapy for chronic lymphocytic leukaemia
9个月前
已关闭
Resistance mutations in CML and how we approach them
11个月前
已关闭
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
1年前
已完结
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
1年前
已完结
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
1年前
已完结
Burden of All Cancers Along With Attributable Risk Factors in China From 1990 to 2019: Comparison With Japan, European Union, and USA
1年前
已完结
Extracellular vesicles mediate the communication of adipose tissue with brain and promote cognitive impairment associated with insulin resistance
1年前
已完结
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia
1年前
已完结
皖公网安备34019202002308
